1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

14 Jan 2023
Admin
News Article

Dr Reddy s acquires trademark rights of breast cancer drug Primcyv from Pfizer to use in India

Hyderabad, Jan. 13 (PTI) Dr. Reddy's Laboratories Ltd. on Friday announced that it has acquired the trademark rights of the breast cancer drug Primcyv from Pfizer ProductsIndia Pvt Ltd for use in the Indian market. Dr. Reddy's Laboratories Ltd. on Friday announced that it has acquired the trademark rights of the breast cancer drug Primcyv from Pfizer ProductsIndia Pvt Ltd for use in the Indian market. Primcyv is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2 metastatic breast cancer, said a press release from the city-based drug-maker. Since May 2022, Dr. Reddy's has been marketing the drug in collaboration with Pfizer Products India under the brandname Primcyv in India. The drug comes in the form of hard capsules in strengths of 75 mg, 100 mg and 125 mg, it further said. Following the trademark rights acquisition, Dr. Reddy's will manufacture the Active Pharmaceutical Ingredient (API) and finished drug at its state-of-the-art facilities approved by the United States Food and Drug Administration (USFDA). Dr. Reddy's is amongst select companies in the world to have conducted a bioequivalence study and received tentative approval from the USFDA for palbociclib. The in-house product will be retailed in the Indian market at a reduction of 85 per cent from the current MRP to increase affordability and access to palbociclib. Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv, it added

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!